Published in Immunol Rev on April 01, 2008
Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology (2009) 4.11
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One (2011) 1.55
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest (2012) 1.27
The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity (2013) 1.17
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
STIM1 and STIM2-mediated Ca(2+) influx regulates antitumour immunity by CD8(+) T cells. EMBO Mol Med (2013) 1.04
Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol (2013) 1.01
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget (2014) 0.92
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog (2014) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int (2013) 0.87
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother (2010) 0.84
Visualizing cancer and immune cell function with metabolic positron emission tomography. Curr Opin Genet Dev (2010) 0.82
Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol (2014) 0.81
Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer. Cancer Sci (2014) 0.76
Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. J Transl Med (2014) 0.75
"Cell biology meets physiology: functional organization of vertebrate plasma membranes"--the immunological synapse. Curr Top Membr (2013) 0.75
Characterization of γδ T cells in patients with non-small cell lung cancer. Oncol Lett (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Preferential localization of effector memory cells in nonlymphoid tissue. Science (2001) 14.22
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Signal transduction by lymphocyte antigen receptors. Cell (1994) 10.63
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Fc receptors. Annu Rev Immunol (1991) 7.92
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell (2002) 5.41
Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev (2006) 4.60
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol (2001) 4.38
Myristylation and palmitylation of Src family members: the fats of the matter. Cell (1994) 4.21
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell (1993) 4.06
Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature (1991) 3.97
Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol (2001) 3.95
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res (1996) 3.73
Does the immune system see tumors as foreign or self? Annu Rev Immunol (2001) 3.71
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev (2004) 3.65
Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol (1996) 3.59
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (2002) 3.46
Siglecs--the major subfamily of I-type lectins. Glycobiology (2005) 3.25
Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science (1995) 3.24
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Compartmentalized Ras/MAPK signaling. Annu Rev Immunol (2006) 3.03
Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci U S A (1989) 2.99
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 2.96
Protein tyrosine phosphatases and the immune response. Nat Rev Immunol (2005) 2.88
Signal transduction by the TCR for antigen. Curr Opin Immunol (2000) 2.87
Hyperresponsive B cells in CD22-deficient mice. Science (1996) 2.86
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol (1999) 2.80
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56
Immunoreceptor tyrosine-based inhibition motifs. Immunol Today (1997) 2.46
The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today (1989) 2.41
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol (2002) 2.26
S-acylation of LCK protein tyrosine kinase is essential for its signalling function in T lymphocytes. EMBO J (1997) 2.19
Immunodepression and malignancy. Adv Cancer Res (1975) 2.17
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation. Proc Natl Acad Sci U S A (1989) 2.15
Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med (1997) 2.06
Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. Mol Biol Cell (2001) 2.02
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science (1996) 1.99
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Essential role of Gab1 for signaling by the c-Met receptor in vivo. J Cell Biol (2000) 1.97
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol Cell Biol (2000) 1.92
Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation. Mol Cell Biol (1988) 1.90
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89
T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics (1989) 1.84
Regulation of pp56lck during T-cell activation: functional implications for the src-like protein tyrosine kinases. EMBO J (1987) 1.80
Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med (2001) 1.79
Adaptors and molecular scaffolds in immune cell signaling. Cell (1999) 1.78
Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Immunity (2001) 1.69
Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol (2004) 1.68
Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol (1998) 1.66
Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol (2006) 1.64
Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol (1998) 1.63
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol (2002) 1.55
Multivalent structure of an alphabetaT cell receptor. Proc Natl Acad Sci U S A (1999) 1.52
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
Tumor-induced immune dysfunction. Cancer Immunol Immunother (1999) 1.47
Integration of T cell receptor-dependent signaling pathways by adapter proteins. Annu Rev Immunol (1999) 1.46
Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res (2002) 1.45
Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal (2002) 1.45
Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol (2003) 1.44
CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol (2001) 1.44
Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol (2005) 1.44
A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med (1996) 1.42
Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. Biochemistry (1994) 1.41
Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res (2003) 1.38
Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology (2002) 1.36
Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother (2004) 1.34
The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J Biol Chem (2002) 1.34
Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol (1999) 1.33
Superantigen-induced T cell:B cell conjugation is mediated by LFA-1 and requires signaling through Lck, but not ZAP-70. J Immunol (2001) 1.30
Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. Proc Natl Acad Sci U S A (1996) 1.29
Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem (2001) 1.29
Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J Biol Chem (2001) 1.29
Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother (1999) 1.29
Lad, an adapter protein interacting with the SH2 domain of p56lck, is required for T cell activation. J Immunol (1999) 1.25
CD4 and CD8: modulators of T-cell receptor recognition of antigen and of immune responses? Curr Opin Immunol (1998) 1.23
TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 1.23
Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat (2004) 1.22
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol (2006) 1.20
Initiation of TCR signaling: regulation within CD3 dimers. Immunol Rev (2003) 1.20
Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol (2005) 1.44
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol (2006) 1.20
Defective adhesion in tumor infiltrating CD8+ T cells. J Immunol (2006) 1.00
Protein kinase Cdelta regulates antigen receptor-induced lytic granule polarization in mouse CD8+ CTL. J Immunol (2007) 0.97